Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vertex PharmaceuticalsMEX:VRTX -0.66%91 Return-on-Tangible-Asset is 16.81% as of Mar. 2026, which is 10% below its 10-year median of 18.69. GuruFocus rates MEX:VRTX with a GF Score™ of 91/100 and a GF Value™ of MXN8,914.24 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Vertex Pharmaceuticals ranks better than 95.13% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vertex Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN74,396 Mil. Vertex Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2026 was MXN442,455 Mil. Therefore, Vertex Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 16.81%.
The historical rank and industry rank for Vertex Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
MEX:VRTX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -4.74 Med: 18.69 Max: 43.4
Current: 18.65
During the past 13 years, Vertex Pharmaceuticals's highest Return-on-Tangible-Asset was 43.40%. The lowest was -4.74%. And the median was 18.69%.
MEX:VRTX's Return-on-Tangible-Asset is ranked better than 95.13% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs MEX:VRTX: 18.65
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vertex Pharmaceuticals Return-on-Tangible-Asset Related Terms
Vertex Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VRTX vs REGN, ALNY, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 16.81% mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Return-on-Tangible-Asset of 16.81% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vertex Pharmaceuticals and its competitors. This is 10% below median its historical median of 18.69. According to the industry distribution chart, Vertex Pharmaceuticals ranks #69 out of 1416 companies in the Biotechnology industry, placing it in the top 4.9%.
Is Vertex Pharmaceuticals' Return-on-Tangible-Asset too high?
Vertex Pharmaceuticals' current Return-on-Tangible-Asset of 16.81% is 10% below median its 10-year median of 18.69. Based on the distribution chart, Vertex Pharmaceuticals ranks #69 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Return-on-Tangible-Asset compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #69 out of 1416 companies for Return-on-Tangible-Asset. This places Vertex Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Return-on-Tangible-Asset is 16.81%, which is 10% below median its own 10-year median of 18.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,914.24, compared to a current price of MXN8,474.00 — trading 4.9% below its estimated fair value. The current Return-on-Tangible-Asset is 16.81%, which is 10% below median its 10-year median of 18.69. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Return-on-Tangible-Asset is 16.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,474.00 is trading 4.9% below its estimated GF Value™ of MXN8,914.24.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
Return-on-Tangible-Asset: 16.81% (10% below median its 10-year median of 18.69)
GF Value™: MXN8,914.24 vs. price of MXN8,474.00 (4.9% below fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for MEX:VRTX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
